<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623569</url>
  </required_header>
  <id_info>
    <org_study_id>A130901CSPF01</org_study_id>
    <nct_id>NCT02623569</nct_id>
  </id_info>
  <brief_title>To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina</brief_title>
  <official_title>Evaluation of the Anti-anginal Efficacy and Safety of Ivabradine Used in Patients With Stable Effort Angina Pectoris. A 12 Weeks Randomised, Double-blind Controlled, Parallel-group, Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xintong Pharmacy Company</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xintong Pharmacy Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arms Assigned Interventions&#xD;
&#xD;
      Experimental: Ivabradine Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day&#xD;
      when positive ETT and HR&gt;60times/min or negative ETT and HR&gt;80times/min of subjects.&#xD;
&#xD;
      Active Comparator: Atenolol Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a&#xD;
      day when positive ETT and heard rate&gt;60times/min or negative ETT and HR &gt;80times/min of&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Washout period：Chronic angina patients stop using medicine that affect heart rate. The&#xD;
           patients undergoes ETT after 2-7 days and positive ETT into the treatment period(If not&#xD;
           take similar medicine, patients can be carried out ETT directly)。&#xD;
&#xD;
        2. Treatment period：Patients carried out ETT after therapy with Ivabradine(5mg,bid)/&#xD;
           Atenolol(12.5mg,bid) for 4 weeks.The dose adjust base on test result and heart rate,&#xD;
           Ivabradine(5mg,bid)/Atenolol(12.5mg,bid) or Ivabradine(7.5mg,bid)/ Atenolol(25mg,bid)&#xD;
           for 8 weeks and carried out ETT.&#xD;
&#xD;
        3. security period：After the treatment period, all patients to take Atenolol 12.5mg/ 25mg&#xD;
           bid 1 week.&#xD;
&#xD;
      If heart rate are low 50 times/min after taking Ivabradine 5mg/ Atenolol 12.5mg, subjects&#xD;
      should withdrawal and dropped out study. If subjects heart rate are low 50 times/min after&#xD;
      taking Ivabradine 7.5mg/ Atenolol 25mg, subjects should change the dose to Ivabradine 5mg/&#xD;
      Atenolol 12.5mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is Change from total exercise duration in exercise tolerance test (ETT)</measure>
    <time_frame>Baseline and end of treatment (Week 12) .</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to angina in exercise tolerance test.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 1 mm ST-segment depression in exercise tolerance test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of angina attacks in exercise tolerance test per week</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sublingual nitroglycerin consumption per week</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR（heard rate）&gt;60times/min or negative ETT and HR（heard rate）&gt;80times/min of subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and HR（heard rate）&gt;60times/min or negative ETT and HR （heard rate）&gt;80times/min of subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Not Provided</description>
    <arm_group_label>Ivabradine</arm_group_label>
    <other_name>Not Provided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Not Provided</description>
    <arm_group_label>Atenolol</arm_group_label>
    <other_name>Not Provided</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male or female aged 18 to 75 years&#xD;
&#xD;
          2. Clearly understand the study and participate in it voluntarily; the informed consent&#xD;
             should be signed in person or by legal guardian.&#xD;
&#xD;
          3. Chronic Stable Angina was confirmed by clinic over 3 months.&#xD;
&#xD;
          4. Patients with clinical diagnosis of chronic stable angina and must meet one of the&#xD;
             following conditions:&#xD;
&#xD;
               -  Patients who have a history of myocardial infarction over 3 months.&#xD;
&#xD;
               -  Patients who have received coronary intervention or CABG（Coronary Artery Bypass&#xD;
                  Grafting） over 6 months.&#xD;
&#xD;
               -  Stenosis of more than 50% in at least one major epicardial coronary artery shown&#xD;
                  by Coronary Angiograph.&#xD;
&#xD;
               -  Ischemic electrocardiogram changes：ST-segment depression ≥ 1.0 mm compared with&#xD;
                  P-R or elevate≥1.0 mm during exercise ECG Computed Tomography Angiography (CTA)&#xD;
                  showed more than 50% stenosis with typical angina symptoms&#xD;
&#xD;
          5. ultrasonic cardiogram disclosed that left ventricular ejection fraction ≥50 %.&#xD;
&#xD;
          6. Patients who manifested positive ETT (exercise tolerance testing) (defined as&#xD;
             ST-segment depression ≥ 1 mm compared with at rest, with or without limiting angina)&#xD;
             at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant Valvular disease, congenital heart disease, pulmonary&#xD;
             hypertension, cerebral apoplexy, dissecting aneurysm, hypertrophic cardiomyopathy,&#xD;
             acute myocarditis/cp.&#xD;
&#xD;
          2. Patients with myocardial infarction within the preceding 3 months&#xD;
&#xD;
          3. Patients have received Coronary angioplasty or CABG within the preceding 6 months.&#xD;
&#xD;
          4. Patients who have severity vessels disease with left main coronary artery but have no&#xD;
             valid treatment.&#xD;
&#xD;
          5. Patients with congestive heart failure(New York Heart Association class III or IV)or&#xD;
             acute pulmonary edema.&#xD;
&#xD;
          6. Patients whose rest heart rate&lt; 60 bpm.&#xD;
&#xD;
          7. Patients with nonrespiratory sinus arrhythmia or&#xD;
             arrhythmia(e.g.,AVB(auriculo-ventricular block)ⅡⅢ,atrial fibrillation,atrial&#xD;
             flutter,SSS(sick sinus syndrome)) or implantable cardiac defibrillator (ICD).&#xD;
&#xD;
          8. Patient with any conditions that interfered the performance of exercise tolerance test&#xD;
             or a history of an abnormal exercise response limited by electrocardiograph (ECG)&#xD;
             changes.&#xD;
&#xD;
          9. Patient with uncontrolled hypertension (seated systolic blood pressure (SBP）≥180 mmHg&#xD;
             or diastolic blood pressure (DBP) ≥100 mmHg); SBP&lt;90 mmHg and/or DBP&lt;60 mmHg&#xD;
&#xD;
         10. Diabetic with uncontrolled blood glucose(FBG≥11.1 mmol/L and/or RBG≥13.6 mmol/L）&#xD;
&#xD;
         11. Patients with anemia(male:Hb≤120 g/L；female：Hb≤110 g/L)&#xD;
&#xD;
         12. Patients complicated with systemic diseases included thyroid&#xD;
             dysfunction、glaucoma、cataract，neurological、mental、psychological disease and any other&#xD;
             disease that influence the judgment.&#xD;
&#xD;
         13. Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.).&#xD;
&#xD;
         14. Patients with mental or legal disorder.&#xD;
&#xD;
         15. Patients who were suspected addicted into alcohol or drug abuse or with severe&#xD;
             complications that would make the condition more complicated assessed by the&#xD;
             investigator.&#xD;
&#xD;
         16. People have liver or renal dysfunction (ALT≥2×ULN、AST≥2×ULN、eGFR≤60ml/min/1.73m2）&#xD;
&#xD;
         17. Patients who should use unapproved drug during the study.&#xD;
&#xD;
         18. Patients who accepted amiodarone(in recent 3 months)and/or benzetimide、βblockers（in&#xD;
             recent 7 days)、&#xD;
&#xD;
         19. Patients with history of allergy or suspected allergic to the drug（e.g.，Hydrochloric&#xD;
             ivabradine,atenolol, βblockers）or lactose.&#xD;
&#xD;
         20. Woman who disagree with contraception during treatment period ，with pregnancy,&#xD;
             lactation or positive result of pregnancy test.&#xD;
&#xD;
         21. Patients with Chronic Obstructive Pulmonary Disease (COPD) requiring bronchodilators.&#xD;
&#xD;
         22. Patients who is participating in other trials or has been participated in other trials&#xD;
             in recent 3 months&#xD;
&#xD;
         23. Patients who were unable to participate in the study as judged by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guizhou Provincial People's Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Zhang</last_name>
      <phone>0851-5623033</phone>
      <email>xin7110p@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genshan Ma</last_name>
      <phone>025-83272038</phone>
      <email>Magenshan@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Shenyang Military</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaling Han</last_name>
      <phone>024-28897309</phone>
      <email>hanyaling@263.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>November 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>December 4, 2015</last_update_submitted>
  <last_update_submitted_qc>December 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

